Pulmatrix, Inc. Common Stock, also called Pulmatrix, is a clinical stage biotechnology company, which engages in the discovery and development of novel inhaled therapeutic products. Read More The firm focuses on the prevention and treatment of respiratory diseases and infections. It offers products based on its proprietary dry powder delivery technology, iSPERSE, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The company was founded by David Alan Edwards, Mark J. Gabrielson, Alexander M. Klibanov and Robert S. Langer, Jr. on June 15, 2015 and is headquartered in Lexington, MA.